Combined Metabolic Activators Improve Cognitive Functions in Alzheimer’s Disease Patients: A Randomized, Double-Blinded, Placebo-Controlled Phase-II Trial

Objective

To investigate whether supplementation of combined metabolic activators (CMA) consisting of L-carnitine tartrate, nicotinamide riboside (NR), serine, and N-acetyl-L-cysteine (NAC), could affect the global metabolism and brain function of Alzheimer’s disease (AD) patients and be used for treatment of the disease.

Study Design

Randomized, double-blind, placebo-controlled, phase II study in 69 AD patients

Dose

2000 mg

One dose of 12.35g L-serine, 1g NR, 2.55g N-acetyl-L-cysteine, and 3.73g L-carnitine tartrate for the first 28 days and two doses for the next 56 days.

Duration

8 weeks

Key Outcomes

  • CMA supplementation improved cognitive function by 29% in AD patients. Patients with high ADAS-Cog scores (worsened cognitive function) showed improvement with CMA supplementation.

  • CMA also improved serum markers related to AD, as well as markers of liver and kidney health in AD patients, as seen through significant decreases in levels of ALT and uric acid.

Clinical, Alzheimer's Disease, Neurological HealthANAD StaffNeurological Health, Alzheimer's Disease